Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals. Learn more at www.symbiomix.com.
Location: United States, New Jersey, Newark
Employees: 51-200
Total raised: $41M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| - | Eight Road... | eightroads... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.05.2015 | Series A | $41M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 07.05.2015 | Symbiomix Therapeutics closes $41M Series A | With a third infusion of investment, Symbiomix Therapeutics closed a $41 million Series A round, the... | technical.... |
| 06.05.2015 | Symbiomix Therapeutics Lands $41M Financing | NEWARK, NJ, Symbiomix Therapeutics today announced multiple milestones, including the closing of t... | vcnewsdail... |
| 06.05.2015 | Symbiomix Therapeutics Closes $41M Series A Financing | Symbiomix Therapeutics, a Newark, N.J.-based late-stage, privately held biopharmaceutical company, c... | finsmes.co... |
| 09.03.2015 | Symbiomix Therapeutics is working on a single-dose treatment... | Bacterial vaginosis (BV) infects about 20 million women in the U.S. every year. As a result of contr... | technical.... |